普洛藥業(000739.SZ):頭孢克肟片和頭孢克肟顆粒擬中選第七批國採
格隆匯7月13日丨普洛藥業(000739.SZ)公佈,2022年7月12日,公司下屬公司浙江普洛康裕製藥有限公司及浙江巨泰藥業有限公司參加了國家組織藥品聯合採購辦公室組織的第七批全國藥品集中採購,公司產品頭孢克肟片和頭孢克肟顆粒擬中選該次集中採購。
公司該次擬中選品種頭孢克肟片於2021年5月取得《藥品補充申請批件》,頭孢克肟顆粒於2021年9月取得《藥品註冊證書》,上述兩個品種均已通過仿製藥質量和療效一致性評價,2021年合計銷售收入為3445.47萬元,佔公司製劑銷售總收入的3.97%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.